SG10201804952QA - Glucosylceramide synthase inhibitors - Google Patents
Glucosylceramide synthase inhibitorsInfo
- Publication number
- SG10201804952QA SG10201804952QA SG10201804952QA SG10201804952QA SG10201804952QA SG 10201804952Q A SG10201804952Q A SG 10201804952QA SG 10201804952Q A SG10201804952Q A SG 10201804952QA SG 10201804952Q A SG10201804952Q A SG 10201804952QA SG 10201804952Q A SG10201804952Q A SG 10201804952QA
- Authority
- SG
- Singapore
- Prior art keywords
- glucosylceramide synthase
- synthase inhibitors
- inhibitors
- glucosylceramide
- gcs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Abstract
GLUCOSYLCERAMIDE SYNTHASE INHIBITORS The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of 5 metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy. [No Figure] 10
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361914842P | 2013-12-11 | 2013-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201804952QA true SG10201804952QA (en) | 2018-07-30 |
Family
ID=52282918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201804952QA SG10201804952QA (en) | 2013-12-11 | 2014-12-09 | Glucosylceramide synthase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20160361301A1 (en) |
| EP (1) | EP3079695B1 (en) |
| CN (2) | CN105979945A (en) |
| CA (1) | CA2931981C (en) |
| ES (1) | ES2871416T3 (en) |
| IL (1) | IL245737B (en) |
| PL (1) | PL3079695T3 (en) |
| PT (1) | PT3079695T (en) |
| SG (1) | SG10201804952QA (en) |
| WO (1) | WO2015089067A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| WO2019126776A1 (en) | 2017-12-21 | 2019-06-27 | Lysosomal Therapeutics Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
| CN113645969A (en) | 2019-02-04 | 2021-11-12 | 建新公司 | Methods for treating symptoms and disorders associated with lysosomal storage disorders |
| US20220274982A1 (en) | 2019-07-29 | 2022-09-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2021020362A1 (en) | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | Heterocyclic compound |
| CA3166777A1 (en) | 2020-02-03 | 2021-08-12 | Nigel Patrick Somerville CRAWFORD | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| AU2021311131A1 (en) | 2020-07-24 | 2023-03-23 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
| CN112798727B (en) * | 2021-04-09 | 2021-07-06 | 宝枫生物科技（北京）有限公司 | Biomarker F7 for diagnosing leukoencephalopathy and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009010557A (en) * | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Method for the treatment of fabry disease using pharmacological chaperones. |
| CA2830540C (en) * | 2011-03-18 | 2021-04-27 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| MA37975B2 (en) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Glucosylceramide synthase inhibitors |
| JO3713B1 (en) * | 2013-03-15 | 2021-01-31 | Genzyme Corp | SALT FORMS OF (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate |
-
2014
- 2014-12-09 US US15/108,686 patent/US20160361301A1/en not_active Abandoned
- 2014-12-09 PT PT148242456T patent/PT3079695T/en unknown
- 2014-12-09 WO PCT/US2014/069338 patent/WO2015089067A1/en active Application Filing
- 2014-12-09 CA CA2931981A patent/CA2931981C/en active Active
- 2014-12-09 EP EP14824245.6A patent/EP3079695B1/en active Active
- 2014-12-09 SG SG10201804952QA patent/SG10201804952QA/en unknown
- 2014-12-09 CN CN201480075230.2A patent/CN105979945A/en active Pending
- 2014-12-09 PL PL14824245T patent/PL3079695T3/en unknown
- 2014-12-09 CN CN202311444367.8A patent/CN117679415A/en active Pending
- 2014-12-09 ES ES14824245T patent/ES2871416T3/en active Active
-
2016
- 2016-05-19 IL IL245737A patent/IL245737B/en active IP Right Grant
-
2018
- 2018-04-05 US US15/946,355 patent/US20190046509A1/en not_active Abandoned
-
2022
- 2022-05-25 US US17/824,552 patent/US20220409595A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2931981A1 (en) | 2015-06-18 |
| WO2015089067A1 (en) | 2015-06-18 |
| US20220409595A1 (en) | 2022-12-29 |
| EP3079695B1 (en) | 2021-03-17 |
| PT3079695T (en) | 2021-05-04 |
| CA2931981C (en) | 2022-05-03 |
| US20190046509A1 (en) | 2019-02-14 |
| IL245737A0 (en) | 2016-07-31 |
| IL245737B (en) | 2020-04-30 |
| CN105979945A (en) | 2016-09-28 |
| PL3079695T3 (en) | 2021-09-27 |
| US20160361301A1 (en) | 2016-12-15 |
| EP3079695A1 (en) | 2016-10-19 |
| ES2871416T3 (en) | 2021-10-28 |
| CN117679415A (en) | 2024-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008428A (en) | Glucosylceramide synthase inhibitors. | |
| TN2015000091A1 (en) | Glucosylceramide synthase inhibitors | |
| SG10201804952QA (en) | Glucosylceramide synthase inhibitors | |
| MX2016003486A (en) | Glucosylceramide synthase inhibitors for the treatment of diseases. | |
| MX2015012502A (en) | Dna-pk inhibitors. | |
| WO2012104007A3 (en) | 7-azaindole derivatives | |
| TN2015000427A1 (en) | Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate | |
| MX2015012842A (en) | Method of preparing glucosylceramide synthase inhibitors. | |
| MX2016005437A (en) | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxami de derivatives as glucosylceramide synthase inhibitors. | |
| GEP20166489B (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| BR112018008931A2 (en) | "compounds for treating hypoproliferative disorders" | |
| MX2017000184A (en) | Enzyme interacting agents. | |
| TN2013000368A1 (en) | Glucosylceramide synthase inhibitors | |
| UA59700U (en) | Method for treating metabolic syndrome |